What is Retatrutide?
Retatrutide is a next-generation triple agonist peptide developed to target three key metabolic receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This tri-agonist mechanism represents a significant advancement over earlier dual-agonist compounds, offering superior metabolic modulation across multiple pathways.
Mechanism of Action
By activating all three receptors concurrently, Retatrutide delivers a multi-pronged metabolic effect:
- GLP-1 Agonism: Reduces appetite, slows gastric emptying, and improves insulin secretion in a glucose-dependent manner.
- GIP Agonism: Enhances insulin sensitivity, supports fat metabolism, and may amplify the appetite-suppressing effects of GLP-1.
- Glucagon Agonism: Increases energy expenditure and promotes hepatic fat oxidation, directly targeting visceral adiposity.
This combination results in pronounced reductions in body weight, improved glycaemic control, and favourable changes in lipid profiles — effects that exceed those observed with single or dual receptor agonists.
Key Research Findings
- Weight Reduction: Phase 2 clinical trials demonstrated mean body weight reductions of up to 24% over 48 weeks — among the highest reported for any pharmacological intervention.
- Metabolic Improvement: Significant reductions in HbA1c, fasting glucose, triglycerides, and LDL cholesterol observed across trial cohorts.
- Liver Fat Reduction: Marked decreases in hepatic fat content, with implications for non-alcoholic fatty liver disease (NAFLD) management.
- Cardiovascular Markers: Improvements in blood pressure and inflammatory markers associated with cardiovascular risk.
Important Notes
Retatrutide is sold strictly for research purposes. All information provided is based on clinical trial and preclinical data. This content is not intended as medical advice. Consult a qualified healthcare professional before use.